List of Excipients in Branded Drug APEXICON E

« Back to Dashboard

Generic Drugs Containing APEXICON E

Company	Ingredient	NDC	Excipient
PharmaDerm a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	10337-395	CETYL ALCOHOL
PharmaDerm a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	10337-395	MINERAL OIL
PharmaDerm a division of Fougera Pharmaceuticals Inc	diflorasone diacetate	10337-395	POLYSORBATE 60

What are the Most Frequently-Used Excipients in APEXICON E?

# Of NDCs	Excipient
2	CETYL ALCOHOL
2	MINERAL OIL
2	POLYSORBATE 60

Apexicon E Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Apexicon E is a prescription topical corticosteroid containing desoximetasone 0.05% in an emollient cream vehicle. Its commercial value is tied less to the active pharmaceutical ingredient, which is an established generic corticosteroid, and more to vehicle performance, tolerability, sensory properties, manufacturing consistency, and regulatory substitutability. The strongest opportunities are generic or branded-generic development, differentiated emollient vehicles, packaging improvements, and lifecycle extensions that improve patient adherence without changing the active ingredient or labeled strength.

What is Apexicon E and how is it positioned?

Apexicon E is a topical emollient cream indicated for corticosteroid-responsive dermatoses. Desoximetasone is a high-potency topical corticosteroid generally positioned for inflammatory skin conditions requiring more activity than low- or moderate-potency agents. The "E" designation identifies the emollient cream presentation rather than a fundamentally different active ingredient.

Attribute	Apexicon E
Active ingredient	Desoximetasone
Strength	0.05%
Dosage form	Topical emollient cream
Therapeutic class	Corticosteroid
Route	Cutaneous
Prescription status	Prescription drug
Primary use	Corticosteroid-responsive dermatoses
Competitive set	Desoximetasone creams, ointments, gels and sprays; other high-potency topical corticosteroids
Key differentiation	Emollient vehicle and topical delivery characteristics

The product competes in a mature market. As a result, commercial differentiation depends on formulation attributes that physicians, pharmacists, payers and patients can recognize, including spreadability, skin feel, absorption, residue, irritation potential, container usability and supply reliability.

What excipients are used in Apexicon E?

The FDA labeling for Apexicon E identifies an emollient cream vehicle containing conventional dermatologic excipients. Public labeling identifies ingredients including cetostearyl alcohol, glyceryl monostearate, isopropyl myristate, mineral oil, polysorbate 60, propylene glycol, purified water, sorbitan monostearate and stearyl alcohol.[1]

Excipient or excipient group	Primary formulation function	Commercial relevance
Cetostearyl alcohol	Consistency agent, emollient, co-emulsifier	Controls viscosity and cream structure
Glyceryl monostearate	Emulsifier and consistency agent	Supports oil-in-water cream stability
Isopropyl myristate	Emollient and spreading agent	Improves slip and reduces drag during application
Mineral oil	Occlusive emollient	Supports moisturization and barrier effect
Polysorbate 60	Nonionic emulsifier	Helps stabilize the emulsion
Propylene glycol	Humectant and solvent	Supports hydration and ingredient dispersion
Purified water	Continuous aqueous phase	Main vehicle component
Sorbitan monostearate	Lipophilic emulsifier	Works with polysorbate systems to stabilize the cream
Stearyl alcohol	Thickener, emollient and co-emulsifier	Affects texture, viscosity and stability

The excipient system is conventional for topical dermatology. That reduces basic formulation risk but also limits product differentiation unless a developer creates a measurable improvement in performance or patient acceptability.

How does the Apexicon E vehicle affect product performance?

The vehicle determines how desoximetasone is deposited, released and distributed on the skin. It also influences adherence, particularly for chronic or recurrent inflammatory dermatoses.

The oil-in-water cream architecture provides a balance between emollience and cosmetic acceptability. Mineral oil supplies occlusion, while fatty alcohols and glyceryl monostearate provide body and structure. Isopropyl myristate improves spreadability and can affect the rate at which the product feels absorbed. Propylene glycol contributes humectancy and may improve solubilization, but it can cause irritation or stinging in some patients with compromised skin barriers.

The formulation strategy therefore has several tradeoffs:

• More mineral oil can increase occlusion but may make the product greasy.
• More fatty alcohol can improve cream body but may reduce spreadability.
• More propylene glycol can support hydration and solvent capacity but may increase irritation risk.
• More emulsifier can improve physical stability but may alter skin feel.
• Lower viscosity can improve dispensing and application but may increase phase-separation risk or leakage from tubes.

For Apexicon E, the commercial target is a stable, sufficiently occlusive cream that remains acceptable for routine use on affected skin. The formulation should avoid excessive greasiness because patients often reduce application frequency when a topical product feels heavy or leaves visible residue.

What formulation opportunities exist for Apexicon E competitors?

Low-irritancy and sensitive-skin formulations

A differentiated product could reduce or replace excipients associated with stinging, sensitization or poor tolerability. Potential development targets include:

• Lower propylene glycol content or an alternative humectant system.
• Reduced emulsifier load.
• Fragrance-free and essential-oil-free positioning.
• Lower residual solvent and impurity profiles.
• Alternative preservative systems, where technically and microbiologically appropriate.

Any excipient change must preserve potency, uniformity, microbial quality, physical stability and drug release. The regulatory burden is higher when the new vehicle materially changes product performance.

Improved sensory profile

A cream with faster rub-in, less tack and reduced residue could compete directly with an incumbent product even if the active ingredient and strength remain unchanged. Sensory attributes can be assessed through controlled human-use studies covering:

• Spreadability.
• Absorption time.
• Greasiness.
• Whitening or visible residue.
• Tackiness.
• Skin softness.
• Odor.
• Application comfort.

These claims require substantiation. A company should avoid unsupported superiority claims based only on laboratory viscosity measurements.

Barrier-support positioning

The emollient system can be optimized for patients with dry, scaly or barrier-impaired skin. Potential approaches include incorporation of physiologic lipids, ceramide systems, cholesterol, fatty acids or other barrier-supportive materials. Such changes create a more differentiated product but also increase development complexity.

A barrier-support formulation may be commercially attractive in atopic dermatitis and xerotic inflammatory conditions, although the product must remain within the regulatory boundaries of a drug. Claims that imply treatment of a distinct disease or restoration of skin barrier function may require clinical support and careful labeling analysis.

Packaging and dose-control improvements

Packaging is a practical lifecycle opportunity. Options include:

• Laminated tubes with improved compatibility.
• Airless pumps that reduce hand contamination.
• Unit-dose or small-dose packages for travel and adherence.
• Child-resistant packaging where commercially justified.
• Large-format packaging for high-use patients, subject to stability and labeling requirements.

The container-closure system must protect the cream from water loss, contamination, light exposure and interaction with the formulation. Packaging changes can create meaningful commercial differentiation without changing the excipient list.

What FDA regulatory pathway applies to Apexicon E alternatives?

A chemically equivalent desoximetasone cream would generally be developed through the abbreviated new drug application pathway if the reference product and regulatory conditions support an ANDA. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements.

For topical products, formulation sameness is commercially important. Changes in inactive ingredients may affect the evidence package, particularly when they influence viscosity, drug release, particle size, globule structure, skin permeation or local tolerability.

Key development controls include:

1. Qualitative and quantitative excipient characterization.
2. Assay and content uniformity.
3. Globule-size and microscopic structure analysis.
4. Rheology and viscosity profiling.
5. In vitro release testing.
6. Microbial limits and preservative effectiveness.
7. Accelerated and long-term stability.
8. Container-closure compatibility.
9. Comparative dermatopharmacokinetic or clinical studies where required.

A formulation that departs materially from the reference product may require more extensive evidence than a compositionally similar generic. The lower-cost strategy is usually a Q1/Q2-aligned vehicle that minimizes clinical and regulatory risk. The higher-value strategy is a differentiated vehicle supported by performance and patient-use data.

What patents protect Apexicon E and its formulation?

The active ingredient, desoximetasone, is an established corticosteroid and is not the principal source of current exclusivity value. Commercial protection is more likely to arise from formulation patents, manufacturing methods, packaging systems, trademarks or proprietary clinical positioning than from the molecule itself.

A patent review should distinguish among:

IP category	Relevance to Apexicon E
Desoximetasone composition-of-matter patents	Expected to be expired or commercially irrelevant for current entry
Cream formulation patents	May protect specific excipient ratios, emulsion systems or release properties
Method-of-use patents	May cover a defined condition, dosing regimen or patient population
Manufacturing patents	May cover mixing, homogenization, temperature control or filling methods
Packaging patents	May cover delivery systems or contamination-control features
Trademark rights	Protect the Apexicon E brand rather than the formulation itself

The FDA Orange Book should be reviewed for any current patent or exclusivity listings associated with the specific Apexicon E NDA. Orange Book status is product- and application-specific; the absence of a listed patent does not eliminate the possibility of unlisted formulation, manufacturing or trademark rights.[2]

For an ANDA applicant, the principal patent risks are:

• A listed formulation patent requiring a Paragraph IV certification.
• Litigation filed within the statutory period after notice.
• A non-listed patent asserted under separate litigation theories.
• Trade-secret protection over manufacturing parameters.
• Difficulty reproducing the reference product's microstructure even when the excipient list is public.

When does Apexicon E lose exclusivity?

Apexicon E's commercial exclusivity depends on the FDA application history, any listed patents, regulatory exclusivity and the status of the product in the FDA's approved-drug databases. A topical corticosteroid product with an established active ingredient generally does not receive new chemical entity exclusivity. The principal entry barrier is therefore usually patent coverage, regulatory requirements and market access rather than molecule-level exclusivity.

The relevant commercial timeline is:

Exclusivity element	Strategic significance
New chemical entity exclusivity	Generally not expected for established desoximetasone
New clinical investigation exclusivity	May apply only if qualifying new studies supported approval
Listed patents	Can delay or complicate ANDA approval
Paragraph IV litigation	May create a 30-month stay in qualifying circumstances
First-filer exclusivity	May apply to an eligible ANDA applicant
Trademark rights	Can restrict branding but do not block an unbranded generic
State substitution and payer policy	Determine the speed of generic uptake

A definitive loss-of-exclusivity date requires the current FDA application record, Orange Book listing and any active patent family analysis. The commercial opportunity is strongest where no enforceable listed patent remains and the incumbent has limited differentiation beyond its vehicle.

What Paragraph IV challenges and litigation risks exist?

A generic applicant must assess every potentially blocking Orange Book patent and determine whether a Paragraph IV certification is justified. The most likely dispute areas for a desoximetasone emollient cream are:

• Whether the proposed vehicle falls within a claimed excipient range.
• Whether the proposed process practices a manufacturing claim.
• Whether the applicant's formulation meets a claimed release or stability limitation.
• Whether a method-of-use patent covers the proposed labeling.
• Whether the patent claims are invalid for anticipation or obviousness.

Topical formulation patents can be difficult to assess because claims may depend on quantitative excipient ranges, rheology, particle or droplet characteristics, pH, water activity or release profiles. Freedom-to-operate analysis should include U.S. continuation and divisional applications, not only the earliest published patent.

No reliable commercial conclusion should be based solely on a search for patents naming "Apexicon E." Patent claims may identify desoximetasone, a broader corticosteroid class, or a vehicle platform without naming the brand.

Which commercial opportunities are strongest?

Generic cream launch

The lowest-risk opportunity is a compositionally aligned desoximetasone 0.05% cream. The value proposition is price, payer coverage, supply reliability and pharmacy substitution. Success depends on securing an approved product with a competitive cost of goods and adequate manufacturing capacity.

Authorized-generic or branded-generic strategy

A manufacturer with access to the reference product or a licensing arrangement could preserve brand recognition while offering a lower-priced channel product. This approach may be useful where prescribers value the emollient presentation but payers demand generic pricing.

Premium vehicle

A premium product could target patients who discontinue topical corticosteroids because of greasiness, residue or irritation. The commercial case requires evidence that the new vehicle produces better patient-reported usability or adherence.

Dermatology portfolio bundling

Desoximetasone cream can be paired commercially with nonsteroidal therapies, moisturizers, cleansers or antifungal products. Bundling can improve prescriber reach and pharmacy presence, although combination claims and co-packaging require regulatory review.

International expansion

Ex-U.S. opportunities depend on local registration, corticosteroid potency classification, prescription controls, local excipient restrictions and reference-product requirements. The same cream may need packaging or excipient changes to meet regional rules.

How does Apexicon E compare with other topical corticosteroid products?

Apexicon E competes against products that differ in potency, vehicle and application characteristics rather than only active ingredient.

Product type	Typical commercial advantage	Main limitation
Desoximetasone cream	Familiar active and established use	Mature generic competition
Desoximetasone ointment	Greater occlusion and barrier effect	Greasier and less acceptable to some users
Desoximetasone gel	Faster-drying sensory profile	May be less suitable for very dry lesions
Desoximetasone spray	Convenient application for selected sites	Higher device and packaging complexity
Other high-potency steroid creams	Broad generic availability	Differing potency, vehicle and payer preferences
Nonsteroidal topical agents	Avoid corticosteroid-specific concerns	Higher price and different evidence requirements

The key competitive question is whether Apexicon E's emollient vehicle creates enough patient or prescriber value to resist automatic substitution. In a mature topical market, an unprotected cream with no clear sensory or adherence advantage is vulnerable to price erosion.

Key Takeaways

• Apexicon E is a desoximetasone 0.05% emollient cream.
• Its excipient system is a conventional oil-in-water dermatologic vehicle built around fatty alcohols, mineral oil, emulsifiers, propylene glycol and purified water.
• The strongest differentiation opportunities are low-irritancy formulation, improved spreadability, reduced residue, barrier-supportive excipients and better packaging.
• Generic entry is more likely to be constrained by formulation performance, patent claims and regulatory evidence than by active-ingredient exclusivity.
• Orange Book status and the current FDA application record determine the relevant patent and exclusivity position.
• A compositionally aligned ANDA is the lowest-risk commercial strategy.
• Premium vehicle development has higher upside but requires comparative performance, tolerability or usability evidence.
• No product-specific revenue estimate should be assigned without verified sales data from the sponsor, IQVIA, Symphony Health or comparable commercial sources.

FAQs

Is Apexicon E a steroid cream?

Yes. Apexicon E contains desoximetasone, a topical corticosteroid, at a 0.05% strength.

Which excipient in Apexicon E provides the most occlusion?

Mineral oil is the principal occlusive emollient identified in the public product labeling. The fatty alcohols also contribute to emollience and cream structure.

Can a generic manufacturer change the excipients in Apexicon E?

Yes, but the change may increase regulatory and bioequivalence requirements. Excipient changes can affect drug release, skin permeation, irritation, stability and physical characteristics.

Is a preservative-free Apexicon E formulation commercially feasible?

It may be feasible if the formulation and packaging achieve acceptable microbiological quality without a conventional preservative system. The product would require supporting stability, microbial and container-closure data.

What is the main patent risk for a generic Apexicon E cream?

The main risks are formulation and manufacturing claims covering excipient ranges, emulsion characteristics, drug release or process parameters. The active ingredient itself is not expected to provide meaningful new-molecule exclusivity.

References

1. DailyMed. (n.d.). Apexicon E: Desoximetasone emollient cream, 0.05% prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase
4. U.S. Food and Drug Administration. (2016). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA guidance materials.